AHN-12 Biodistribution in Advanced Leukemia

Sponsor

Masonic Cancer Center, University of Minnesota (Other)

Overall Status

Terminated

CT.gov ID

NCT01207076

Collaborator

(none)

Enrollment

Location

Arm

Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a single institution phase I study for the treatment of patients with relapsed or refractory leukemia aged 12 years and older using 90Y-AHN-12.

Condition or Disease	Intervention/Treatment	Phase
Acute Myelogenous Leukemia Myelodysplastic Syndrome Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia	Biological: 90Y-AHN-12	Phase 1

Detailed Description

A dose escalation schema will be used with the initial patient receiving the current lowest dose of nonradiolabeled AHN-12 (from 0.20 mg/kg to 1.0 mg/kg). If a favorable biodistribution is not achieved and the patient remains negative for HAMA, the infusion may be repeated up to two more times (with a one level increase in nonradiolabeled AHN-12 each time) in an attempt of achieving favorable biodistribution.

In order to achieve the primary objective of identifying the optimal nonradiolabeled dose of AHN-12 antibody for all patients, if the first patient at the current antibody dose does not achieve favorable biodistribution, the next patient(s) will be treated at the next higher dose level.

Patients achieving favorable biodistribution and remaining negative for HAMA will be eligible for the therapeutic component of this trial. Those not meeting these requirements will be taken off study and followed.

Study Design

Study Type:

Interventional

Actual Enrollment :

8 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 In Patients With Advanced Leukemia HM2010-05

Study Start Date :

Dec 1, 2013

Actual Primary Completion Date :

Jul 1, 2014

Actual Study Completion Date :

Jul 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: receiving AHN-12 and 90Y-AHN-12 Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).	Biological: 90Y-AHN-12 The intervention consists of two parts. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12. Dose escalation of nonradiolabeled AHN-12: Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12. the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy.

Arm

Intervention/Treatment

Experimental: receiving AHN-12 and 90Y-AHN-12

Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).

Biological: 90Y-AHN-12

The intervention consists of two parts. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12. Dose escalation of nonradiolabeled AHN-12: Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12. the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy.

Outcome Measures

Primary Outcome Measures

Optimal Dose of AHN-12 Non-radiolabeled Antibody [Day 2]
doses of nonradiolabeled antibody are specified: 0.20, 0.40, 0.60, 0.80 and 1.00 mg/kg.

Secondary Outcome Measures

Maximum Tolerated Dose (MTD) of 90Y-AHN-12 [Within 14 days of achieving favorable biodistribution]
•Determine the MTD of 90Y-AHN-12 for patients with a favorable biodistribution and a negative human anti-mouse antibody (HAMA). Doses of radiolabeled antibody are specified starting dose level with dose increment of 2 gray (Gy) to maximum of 22 Gy.
Human Anti-Mouse Antibody (HAMA) Response [30 and 90 Days Post Therapy, Then Every 6 Months If Positive]
Event is whether or not the patient develops a HAMA response.
Anti-tumor Activity of 90Y-AHN-12 [30 and 90 Days Post Therapy]
Event is response to therapy: complete remission, partial remission, refractory or relapsed disease.

Eligibility Criteria

Criteria

Ages Eligible for Study:

12 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients must have one of the following histologically confirmed CD45+ diseases. If possible, AHN-12 positivity will be confirmed by flow cytometry on a recent bone marrow or a peripheral blood sample, if circulating blasts are present.
Acute myelogenous leukemia (AML), primary refractory or relapsed disease
Refractory myelodysplastic syndrome (MDS)
AML arising from pre-existing MDS, refractory
Acute lymphoblastic leukemia (ALL), primary refractory or relapsed disease
Chronic myelogenous leukemia (CML) following blast crisis
Age ≥ 12 years
Karnofsky Performance Status ≥ 60% (16 years and older) or Lansky Play Score ≥ 60 (<16 years)
Life expectancy of > 12 weeks in the opinion of the enrolling medical provider
Patients must have adequate organ function
Human anti-mouse antibody (HAMA) must be negative (perform on all patients regardless of prior therapies).
Consent to adequate contraception. The effects of 90Y-AHN-12 on the developing fetus are unknown.
Source of allogeneic stem cells must have been identified in event of severe myelosuppression
Able to give written consent.
Both men and women of all ethnic groups are eligible for this trial.

Exclusion Criteria:

Ongoing grade 2 or greater non-hematologic toxicity due to previously administered therapies
< 8 days from completion of therapy with any biologic agent
Receiving any investigational agents
Active central nervous system (CNS) leukemia are excluded from this clinical trial
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-AHN-12 or other agents used in study.
Uncontrolled illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the enrolling medical provider.
Pregnant and breastfeeding women are excluded from this study because 90Y-AHN-12, being radioactive, as well as high dose chemotherapy and total body irradiation (TBI) have the potential for teratogenic or abortifacient effects.
Human immunodeficiency virus (HIV) positive patients:
< 60 days since an autologous transplant
Bone marrow cellularity <5% (because of concern of myelosuppression)